Medicines that remove the STAT5 protein to fight leukemia and other cancers
Small-molecule degraders of STAT5
New small-molecule drugs are being developed to remove the STAT5 protein in people with AML, CML, or other cancers driven by STAT5 to slow tumor growth.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11162336 on NIH RePORTER |
What this research studies
Researchers are designing small molecules that prompt cancer cells to break down the STAT5 protein rather than just block it. Their early lab work shows these degraders can remove STAT5 in human leukemia cells and shrink tumors in mouse models. The team uses structure-based design and protein crystallography to optimize drug potency, selectivity, and how the drug behaves in the body. If the optimized molecules prove safe and effective, the plan would be to move toward clinical testing in patients with STAT5-driven cancers.
Who could benefit from this research
Good fit: Patients whose leukemia or other tumors show high or hyperactive STAT5 signaling (for example some AML or CML patients) would be the most likely candidates for future trials.
Not a fit: Patients whose cancers do not rely on STAT5 or those needing immediate approved therapies are unlikely to benefit directly from this preclinical work in the short term.
Why it matters
Potential benefit: Could lead to a new targeted treatment that shrinks or controls STAT5-driven cancers such as certain AML and CML cases.
How similar studies have performed: Protein-degrading drugs (PROTAC-type approaches) have shown promise for other difficult targets and this team's cell and mouse data are encouraging, but human benefit has not yet been demonstrated.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wang, Shaomeng — University of Michigan at Ann Arbor
- Study coordinator: Wang, Shaomeng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.